Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study.
Metabolic dysfunction
metabolic syndrome
olanzapine
risperidone
schizophrenia spectrum and other psychotic disorders
triglycerides
Journal
Journal of family medicine and primary care
ISSN: 2249-4863
Titre abrégé: J Family Med Prim Care
Pays: India
ID NLM: 101610082
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
31
10
2021
revised:
02
02
2022
accepted:
04
02
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
9
7
2022
Statut:
ppublish
Résumé
Schizophrenia spectrum and other psychotic disorders are common disorders often requiring long-term treatment with atypical antipsychotics, which might cause metabolic dysfunctions. We aimed to study the metabolic dysfunctions with olanzapine and risperidone in patients with schizophrenia spectrum and other psychotic disorders. We also explored the incidence of new-onset metabolic syndrome and its predictors. This was a 24-week prospective observational study conducted at a teaching hospital in North India. The patients were prescribed olanzapine or risperidone. Anthropometric measurements (waist circumference, weight, body mass index, blood pressure) and biochemical investigations (triglycerides, high-density lipoproteins, fasting plasma glucose) were recorded at baseline and after 24 weeks. Metabolic syndrome was defined using the International Diabetes Federation definition. Statistical tests used were Fisher's exact test, paired t-test, unpaired t-test, and logistic regression. A total of 45 patients, 30 on olanzapine and 15 on risperidone completed the study. Statistically significant changes occurred in all variables with olanzapine while with risperidone statistically significant changes occurred in all variables except waist circumference and fasting plasma glucose. Statistically greater changes in mean values between the two were noted only for high-density lipoprotein with olanzapine. 20% of patients developed metabolic syndrome with non-significant between drug differences. Baseline triglyceride predicted the development of the metabolic syndrome. Olanzapine and risperidone cause metabolic derangements and statistically significant differences may not exist between them. Baseline triglyceride levels might predict subsequent metabolic syndrome.
Sections du résumé
Background and Aims
UNASSIGNED
Schizophrenia spectrum and other psychotic disorders are common disorders often requiring long-term treatment with atypical antipsychotics, which might cause metabolic dysfunctions. We aimed to study the metabolic dysfunctions with olanzapine and risperidone in patients with schizophrenia spectrum and other psychotic disorders. We also explored the incidence of new-onset metabolic syndrome and its predictors.
Methods
UNASSIGNED
This was a 24-week prospective observational study conducted at a teaching hospital in North India. The patients were prescribed olanzapine or risperidone. Anthropometric measurements (waist circumference, weight, body mass index, blood pressure) and biochemical investigations (triglycerides, high-density lipoproteins, fasting plasma glucose) were recorded at baseline and after 24 weeks. Metabolic syndrome was defined using the International Diabetes Federation definition. Statistical tests used were Fisher's exact test, paired t-test, unpaired t-test, and logistic regression.
Results
UNASSIGNED
A total of 45 patients, 30 on olanzapine and 15 on risperidone completed the study. Statistically significant changes occurred in all variables with olanzapine while with risperidone statistically significant changes occurred in all variables except waist circumference and fasting plasma glucose. Statistically greater changes in mean values between the two were noted only for high-density lipoprotein with olanzapine. 20% of patients developed metabolic syndrome with non-significant between drug differences. Baseline triglyceride predicted the development of the metabolic syndrome.
Conclusions
UNASSIGNED
Olanzapine and risperidone cause metabolic derangements and statistically significant differences may not exist between them. Baseline triglyceride levels might predict subsequent metabolic syndrome.
Identifiants
pubmed: 35800481
doi: 10.4103/jfmpc.jfmpc_2161_21
pii: JFMPC-11-2194
pmc: PMC9254779
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2194-2200Informations de copyright
Copyright: © 2022 Journal of Family Medicine and Primary Care.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Schizophr Res. 2005 Dec 1;80(1):131-3
pubmed: 16140504
Bangladesh Med Res Counc Bull. 2015 Dec;41(3):144-150
pubmed: 29870170
Schizophr Res. 2008 Apr;101(1-3):266-72
pubmed: 18262771
Singapore Med J. 2012 Jul;53(7):488-92
pubmed: 22815019
J Psychopharmacol. 2009 Nov;23(8):915-22
pubmed: 18635691
Am J Psychiatry. 2005 Jun;162(6):1217-21
pubmed: 15930076
Lancet Psychiatry. 2020 Feb;7(2):148-161
pubmed: 31879245
Schizophr Res. 2009 May;110(1-3):95-102
pubmed: 19269139
Eur Psychiatry. 2003 Oct;18(6):320-1
pubmed: 14611929
Lancet Psychiatry. 2020 Jan;7(1):64-77
pubmed: 31860457
Psychiatry Res. 2012 Dec 30;200(2-3):1035-7
pubmed: 22503355
Indian J Psychol Med. 2013 Jul;35(3):227-40
pubmed: 24249923
Indian J Psychiatry. 2011 Apr;53(2):128-33
pubmed: 21772644
J Clin Psychiatry. 2007 Nov;68(11):1733-40
pubmed: 18052567
Eur J Clin Pharmacol. 2014 Dec;70(12):1433-41
pubmed: 25291992
Schizophr Res. 2008 Apr;101(1-3):273-86
pubmed: 18258416
Am J Psychiatry. 2003 Feb;160(2):290-6
pubmed: 12562575
Diabetes Metab. 2008 Nov;34(5):490-6
pubmed: 18693056
Indian J Clin Biochem. 2014 Apr;29(2):196-201
pubmed: 24757302
Schizophr Res. 2009 Feb;107(2-3):115-21
pubmed: 18993033
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1273-8
pubmed: 21513765
Am J Psychiatry. 2001 May;158(5):765-74
pubmed: 11329400
Psychopharmacology (Berl). 2006 Jul;186(4):572-8
pubmed: 16601995
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Indian J Physiol Pharmacol. 2009 Jan-Mar;53(1):47-54
pubmed: 19810576
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
J Indian Med Assoc. 2005 Dec;103(12):660-4
pubmed: 16821658